Project description DEENESFRITPL A smart device for the detection of lung fluid congestion Heart failure (HF) causes lung fluid congestion and pulmonary oedema due to the reduced cardiac pumping ability. The diagnosis of lung fluid congestion is often inaccurate, and the condition can only be detected at an advanced stage, leading to deterioration and hospitalisation. The EU-funded EGM project will conduct a feasibility study to introduce to the market a non-invasive system that enables the easy and accurate monitoring of lung fluid accumulation. Early testing indicates that the device - two sets of electrodes embedded inside a wearable vest operating on a specialised software platform - is 98 % accurate and 25-fold more sensitive compared with existing techniques. Moreover, it is cost-effective and has the potential to improve the clinical outcome of HF. Show the project objective Hide the project objective Objective Heart failure (HF) is a major global cause of death, affecting over 26M people, and it represent the most common cause of hospitalisation for people over 65. Over 90% of hospitalisations and deaths in HF patients are caused by lung fluid congestion, a condition caused by the retention of fluids due to the reduced cardiac pumping ability, which can lead to severe pulmonary edema. Current diagnostic practices for detection of lung fluid congestion are mostly inaccurate, meaning that the condition can only be detected in its advanced stages when emergency hospitalisation is required. This results in a high rate of mortality (30% in the EU) and high treatment costs (€11,300 per person on average). CardioSet introduces a non-invasive monitoring system, EGM, that detects lung fluid accumulation at an early and asymptomatic stage in HF patients. EGM comprises two sets of strategically placed electrodes inside a wearable vest, and a lung fluid monitoring software that automatically sends alerts to a desktop or mobile application when accumulation is detected. EGM enables early detection and pre-emptive interventions, reducing mortality and hospitalisation rate. The technique provides 98% accuracy and a 25-fold increase in sensitivity over incumbent techniques whilst being 50% more cost-effective. CardioSet aim to introduce EGM to market to save lives across the globe. During the phase 1 feasibility study, CardioSet will establish a sound go-to-market strategy and supply chain, and will draft further development plans. During the second phase of the innovation project, CardioSet will optimise and miniaturise device components, optimize the software user-interface, and perform clinical validation with partner hospitals. Fields of science natural sciencescomputer and information sciencesinternetinternet of thingsnatural sciencescomputer and information sciencessoftwaresocial sciencessociologydemographymortalitymedical and health sciencesclinical medicinecardiology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator CARDIOSET MEDICAL LTD Net EU contribution € 50 000,00 Address Noa building, 2nd floor, 16 bar kochba road 5120149 Bnei brak Israel See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
